Back

Full professor K.P.M. (Karijn) Suijkerbuijk

Full professor K.P.M. (Karijn) Suijkerbuijk

Full Professor

Show full profile

Research Output (132)

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies

Van Not Olivier J, van den Eertwegh Alfons J M, Haanen John B, van Rijn Rozemarijn S, Aarts Maureen J B, van den Berkmortel Franchette W P J, Blank Christian U, Boers-Sonderen Marye J, van Eijs Mick J M, de Groot Jan-Willem B, Hospers Geke A P, Kapiteijn Ellen, de Meza Melissa, Piersma Djura, Stevense-den Boer Marion, van der Veldt Astrid A M, Vreugdenhil Gerard, Wouters Michel W J M, Suijkerbuijk Karijn P M, Blokx Willeke A M 16 Mar 2023, In: European Journal of Cancer. 186 , p. 27-37 11 p.

Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events-Reply

van Not Olivier J, Verheijden Rik J, Suijkerbuijk Karijn P M 9 Mar 2023, In: JAMA Oncology. 9 , p. 724

Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry

van Breeschoten Jesper, van den Eertwegh Alfons J.M., Hilarius Doranne L., Haanen John B., Blank Christian U., Aarts Maureen J.B., van den Berkmortel Franchette W.P.J., de Groot Jan Willem B., Hospers Geke A.P., Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S., Stevense-den Boer Marion A., van der Veldt Astrid A.M., Vreugdenhil Gerard, Boers-Sonderen Marye J., Manevski Damjan, Suijkerbuijk Karijn P.M., Wouters Michel W.J.M., de Wreede Liesbeth C. Mar 2023, In: European Journal of Cancer. 182 , p. 132-143 12 p.

Adjuvant Treatment of In-Transit Melanoma:Narrowing the Knowledge Gap Left by Clinical Trials

de Meza Melissa M, Blokx Willeke A M, Bonenkamp Han J, Blank Cristian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, Boers-Sonderen Marye J, de Groot Jan Willem B, Haanen John B, Hospers Geke A P, Kapiteijn Ellen W, van Not Olivier J, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion A, van der Veldt Astrid A M, Vreugdenhil Gerard, van den Eertwegh Alfons J M, Suijkerbuijk Karijn P M, Wouters Michel W J M 26 Feb 2023, In: International Journal of Cancer. 153 , p. 389-398 10 p.

CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma

Ter Maat Laurens S, van Duin Isabella A J, Elias Sjoerd G, Leiner Tim, Verhoeff Joost J C, Arntz Eran R A N, Troenokarso Max F, Blokx Willeke A M, Isgum Ivana, de Wit Geraldine A, van den Berkmortel Franchette W P J, Boers-Sonderen Marye J, Boomsma Martijn F, van den Eertwegh Fons J M, de Groot Jan Willem B, Piersma Djura, Vreugdenhil Art, Westgeest Hans M, Kapiteijn Ellen, van Diest Paul J, Pluim Josien P W, de Jong Pim A, Suijkerbuijk Karijn P M, Veta Mitko 24 Feb 2023, In: European Journal of Cancer. 185 , p. 167-177 11 p.

Development and validation of risk calculators for people with "thin" melanomas on their skin to predict the likelihood that their cancer will return:a plain language summary of publication

Sharouni Mary-Ann El, Lo Serigne N, Varey Alexander Hr, Elias Sjoerd G, Witkamp Arjen J, Sigurdsson Vigfús, Suijkerbuijk Karijn Pm, van Diest Paul J, van Gils Carla H, Blokx Willeke Am, Scolyer Richard A, Thompson John F Jan 2023, In: Future Oncology. 19 , p. 97-102 6 p.

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma:A Propensity-Matched Outcome Analysis

De Meza Melissa M., Blokx Willeke A.M., Bonenkamp Johannes J., Blank Christian U., Aarts Maureen J.B., van den Berkmortel Franchette W.P.J., Boers-Sonderen Marye J., De Groot Jan Willem B., Haanen John B.A.G., Hospers Geke A.P., Kapiteijn Ellen, Van Not Olivier J., Piersma Djura, Van Rijn Rozemarijn S., Stevense-den Boer Marion, Van der Veldt Astrid A.M., Vreugdenhil Gerard, Van den Eertwegh Alfonsus J.M., Suijkerbuijk Karijn P.M., Wouters Michel W.J.M. Jan 2023, In: Cancers. 15

Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma

Fraterman Itske, Reijers Irene L M, Dimitriadis Petros, Broeks Annegien, Gonzalez M, Menzies A M M, Lopez-Yurda Marta, Kapiteijn Ellen, van der Veldt Astrid A M, Suijkerbuijk Karijn P M, Hospers Geke A P, Long Georgina V, Blank Christian U, van de Poll-Franse Lonneke V 2023, In: Nature Medicine. 29 , p. 3090-3099 10 p.

Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma

van Duin Isabella A.J., Elias Sjoerd G., van den Eertwegh Alfonsus J.M., de Groot Jan Willem B., Blokx Willeke A.M., van Diest Paul J., Leiner Tim, Verhoeff Joost J.C., Verheijden Rik J., van Not Olivier J., Aarts Maureen J.B., van den Berkmortel Franchette W.P.J., Blank Christian U., Haanen John B.A.G., Hospers Geke A.P., Kamphuis Anna M., Piersma Djura, van Rijn Rozemarijn S., van der Veldt Astrid A.M., Vreugdenhil Gerard, Wouters Michel W.J.M., Stevense-den Boer Marion A.M., Boers-Sonderen Marye J., Kapiteijn Ellen, Suijkerbuijk Karijn P.M. 2023, In: International Journal of Cancer. 152 , p. 2493-2502 10 p.

Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

van der Kooij Monique K, Joosse Arjen, Suijkerbuijk Karijn P M, Aarts Maureen J B, van den Berkmortel Franchette W P J, Blank Christian U, Boers-Sonderen Marye J, van den Eertwegh Alfonsus J M, de Groot Jan Willem B, Haanen John B A G, Hospers Geke A P, Piersma Djura, van Rijn Rozemarijn S, van der Veldt Astrid A M, Vreugdenhil Gerard, Westgeest Hans M, Wouters Michel W J M, Dekkers Olaf M, Kapiteijn Ellen 23 Dec 2022, In: British Journal of Cancer. 128 , p. 707-710 4 p.

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not